As the utilization of AAV vector-based gene therapies grows, there is the need for regulatory compliant analytical platforms for quality control and product release assays. Using AAV2 as a test case, we illustrate how performing HILIC-MS with DFA as a mobile phase modifier, provides clear separation of all three full-length AAV VPs while also providing high quality MS data for AAV characterization.